Bio Medica Laboratories IPO
Price band
₹132 – ₹139
Lot size
1000 shares
Min investment
₹1,39,000
Issue size
₹52.43 Cr
IPO schedule
| Open date | 21 May 2026 |
| Close date | 25 May 2026 |
| UPI mandate cut-off | 25 May 2026 |
| Allotment finalisation | 26 May 2026 |
| Refund initiation | 27 May 2026 |
| Shares credited to demat | 27 May 2026 |
| Listing date | 29 May 2026 |
| Mandate end date | 9 Jun 2026 |
| Anchor lock-in (50%) | 24 Jun 2026 |
| Anchor lock-in (remaining) | 23 Aug 2026 |
Issue size
Grey Market Premium (GMP)
GMP is an unofficial, unregulated indicator and not a reliable predictor of listing price. Source: IPO Watch.
Subscription status
Reserved and applied figures are in crore shares.
About Bio Medica Laboratories
Bio Medica Laboratories Limited is a pharmaceutical company engaged in the manufacturing of pharmaceutical parenteral formulations. The company manufactures generic injectable drugs, including liquid injections and dry powder injections, for both human and veterinary use. Its products are offered in single-dose and multi-dose formats to address a range of medical requirements. The company follows a business-to-business (B2B) model and primarily generates revenue through contract manufacturing arrangements with pharmaceutical companies. Under this model, Bio Medica manufactures formulations based on customer specifications, while the client company markets the products under its own brand name or as a technical collaborator. The company operates manufacturing facilities in Indore, Madhya Pradesh, and focuses on supplying formulations to other pharmaceutical businesses rather than directly selling to end consumers.
Strengths
- Bio Medica manufactures generic injectable drugs for both human and veterinary use.
- The company operates on a B2B contract manufacturing model with pharmaceutical companies.
- Promoters have over 18 years of experience in the pharmaceutical sector.
- The company offers liquid injections and dry powder injections in single and multi-dose formats.
- Revenue and profitability improved significantly in FY25 compared to previous years.
Risks
- Production at Manufacturing Unit-I was suspended due to regulatory non-compliances.
- The company operates from leased properties and does not own its manufacturing premises.
- The business may face conflicts of interest with promoter group entities in similar businesses.
- The company had a high debt-to-equity ratio in previous financial years.
- Failure to renew or maintain licenses and approvals could affect operations.
Use of proceeds
| Repayment of borrowings | ₹6.5 (13.77%) Cr |
| General corporate purposes | ₹12.19 (25.84%) Cr |
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.